Keynote A39: Enfortumab Vedotin + Pembrolizumab agroundbreaking First Line Treatment in Untreated la/mUC
For over four decades, chemotherapy has been the cornerstone of treatment in locally advanced or
metastatic urothelial carcinoma. Today, we are at the cusp of a transformative shift. A groundbreaking combination therapy has emerged, achieving a notable 55% reduction in progression rates and an over 50% decrease in the risk of mortality. Dr. Thomas Powles states that if given the opportunity, he would change his treatment for these patients tomorrow.
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.